Diagnosis and management of paroxysmal nocturnal hemoglobinuria.

By C. Parker, M. Omine, S. Richards, J. Nishimura, M. Bessler, R. Ware, P. Hillmen, L. Luzzatto, N. Young, T. Kinoshita and 2 more. Blood, 2005

797 citations recorded by the source corpus.

Subfields: Genetics, Immunology, Nephrology

View Paper: https://www.semanticscholar.org/paper/e1f0d4d18dc6981ce0d00f6879be157c22f4c402

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

1. L. Bell
2. T. Foukaneli
3. N. Bown
4. S. Samarasinghe
5. G. Mufti
6. J. Cavenagh
7. S. Killick
8. I. Dokal

Citations in the corpus

• Discovery and development of the complement inhibitor eculizumab for the treatment of paroxysmal nocturnal hemoglobinuria (2007, background): “The inability of cells to attach proteins through this lipid moiety is caused by somatic mutations occurring in the X-linked gene, phosphatidylinositol glycan–complementation class A ( PIGA”
• Guidelines for the diagnosis and management of adult aplastic anaemia (2016, background): “Grade 2C 202 ª 2015 John Wiley & Sons Ltd British Journal of Haematology, 2016, 172, 187–207 Paroxysmal nocturnal haemoglobinuria and AA Tests to detect a PNH clone Paroxysmal nocturnal haemoglobinuria should be excluded by performing flow cytometry (Parker et al, 2005; Borowitz et al, 2010).”